Compare XBIO & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIO | TNON |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 2 | 26 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.8M |
| IPO Year | N/A | N/A |
| Metric | XBIO | TNON |
|---|---|---|
| Price | $3.11 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.6K | ★ 62.5K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.81 | $65.95 |
| Revenue Next Year | N/A | $50.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.64 |
| 52 Week High | $13.93 | $2.48 |
| Indicator | XBIO | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 40.28 |
| Support Level | $2.94 | $0.66 |
| Resistance Level | $3.42 | $0.82 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 88.89 | 6.92 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.